Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1

NCT01070823 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01070823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01070823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
March 31, 2010
Completion date
June 30, 2012
Enrollment
1,096 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis